Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...
News-Medical.Net on MSN
CRISPR-based Cellgorithm technology ushers in a new era of cell programming
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Molecular and morphological profiles of developing neurons in vitro uncover the cellular dynamics of human neurodevelopment and related disease.
A gene that turns on very early in embryonic development could be key to the formation of the placenta, which provides the ...
Scalable iPSC neuron manufacturing advances neuroscience, improving disease modeling, therapeutic development, and clinical readiness.
A gene that turns on very early in embryonic development could be key to the formation of the placenta, which provides the ...
When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...
Chennai, Dec. 8 -- Highlights: ...
Elana Thieme and Mark Mendoza, fourth-year graduate students in the Molecular and Cell Biology (MCB) PhD Program jointly ...
CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER‑NSCLC‑02 (GDF‑15 ...
Researchers say in future it may be possible to grow personalized organoids from patient’s own tissue, to test potential treatments in advance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback